The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review
Электронный научный архив УРФУ
Информация об архиве | Просмотр оригинала| Поле | Значение | |
| Заглавие |
The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review
|
|
| Автор |
Xiao, N.
Huang, X. Kang, X. Zang, W. Li, B. Kiselev, S. |
|
| Тематика |
COVID-19
ORAL ANTIVIRAL DRUG PUBLIC HEALTH VACCINES VV116 ANTI-SARS-COV-2 AGENT NIRMATRELVIR PLUS RITONAVIR PLACEBO UNCLASSIFIED DRUG UREA VV 116 ANTIVIRUS AGENT GS-621763 RITONAVIR ADULT ANTIVIRAL THERAPY AREA UNDER THE CURVE CORONAVIRUS DISEASE 2019 DISEASE SEVERITY DRUG ABSORPTION DRUG EFFICACY DRUG SAFETY FEMALE HUMAN LEUKOCYTE COUNT LIPID DIET MALE MAXIMUM CONCENTRATION META ANALYSIS NONHUMAN PLASMA CONCENTRATION-TIME CURVE PUBLIC HEALTH REMISSION REVIEW SYMPTOM SYSTEMATIC REVIEW TIME TO MAXIMUM PLASMA CONCENTRATION UREA BLOOD LEVEL VIRUS SHEDDING AGED CORONAVIRUS DISEASE 2019 AGED ANTIVIRAL AGENTS COVID-19 HUMANS RITONAVIR |
|
| Описание |
Background: Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID-19. However, no comprehensive studies have assessed the safety and efficacy of VV116. Therefore, we conducted a systematic review to assess the safety and efficacy of VV116. Methods: A comprehensive search was conducted on PubMed, Scopus, and Google Scholar websites, with a cutoff date of March 23, to identify pertinent studies. Results: The results from the 3 included studies indicated that no serious adverse events were reported in the VV116 experimental groups, which exhibited a 2.57-day faster time to viral shedding than the control group and demonstrated non-inferiority to the nirmatrelvir-ritonavir control group in alleviating major symptoms. Discussion: Collectively, available studies suggest a reliable safety and efficacy profile for VV116. However, the limited number of trials was insufficient for meta-analysis, and the included population consisted of younger individuals with mild and moderate symptoms, not encompassing the elderly who are severely affected by COVID-19. We hope that more studies will be conducted in the future to ensure that VV116 has a more reliable safety and efficacy profile in the clinical setting, especially in severe or critical patients. © 2023 Lippincott Williams and Wilkins. All rights reserved.
Ural Federal University, UrFU This research was conducted with financial support from Ural Federal University. |
|
| Дата |
2024-04-05T16:27:33Z
2024-04-05T16:27:33Z 2023 |
|
| Тип |
Review
Review (info:eu-repo/semantics/review) |info:eu-repo/semantics/publishedVersion |
|
| Идентификатор |
Xiao, N, Huang, X, Kang, X, Zang, W, Li, B & Kiselev, S 2023, 'The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review', Medicine, Том. 102, № 27, e34105. https://doi.org/10.1097/MD.0000000000034105
Xiao, N., Huang, X., Kang, X., Zang, W., Li, B., & Kiselev, S. (2023). The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review. Medicine, 102(27), [e34105]. https://doi.org/10.1097/MD.0000000000034105 0025-7974 Final All Open Access, Gold, Green https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164260084&doi=10.1097%2fMD.0000000000034105&partnerID=40&md5=03bd105adc8c6866dbed215d69f81cba https://doi.org/10.1097/md.0000000000034105 http://elar.urfu.ru/handle/10995/130627 10.1097/MD.0000000000034105 85164260084 001025647200037 |
|
| Язык |
en
|
|
| Права |
Open access (info:eu-repo/semantics/openAccess)
cc-by-nc https://creativecommons.org/licenses/by-nc/4.0/ |
|
| Формат |
application/pdf
|
|
| Издатель |
Lippincott Williams and Wilkins
|
|
| Источник |
Medicine
Medicine (United States) |
|